TY - JOUR T1 - Adjusting for treatment crossover in the BREAK-3 metastatic melanoma trial for dabrafenib: Preliminary analysis. JO - Journal of Clinical Oncology PY - 2013/05/20 AU - Latimer N AU - Abrams KR AU - Amonkar M AU - Stapelkamp C AU - Swann RS ED - DO - DOI: 10.1200/jco.2013.31.15_suppl.9044 PB - American Society of Clinical Oncology (ASCO) VL - 31 IS - 15_suppl SP - 9044 EP - 9044 Y2 - 2025/05/21 ER -